Novavax coronavirus vaccine induces immune response in early study


Modified 5 Aug 2020, 2:06 am

CORONAVIRUS | Novavax Inc said on Tuesday its experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company's shares up 10 percent.

The company said it would start a large pivotal Phase III trial as soon as late September, and on a conference call added that it could produce one billion to two billion doses of the vaccine in 2021...

Share this story


By posting a comment, you agree to our Terms & Conditions as stipulated in full here


Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.


Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.